Source 1primary paper2026MED
Toolkit/FPV VP2 virus-like particles
FPV VP2 virus-like particles
Also known as: FPV VLPs, VP2 VLPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The purified protein self-assembled into uniform 25 nm virus-like particles (VLPs).
Usefulness & Problems
Why this is useful
These are VP2-derived virus-like particles generated from purified recombinant protein that self-assemble into uniform 25 nm particles. The study presents them as the vaccine antigen produced by the optimized BEVS platform.; FPV vaccine antigen design; safe and immunogenic vaccine development
Source:
These are VP2-derived virus-like particles generated from purified recombinant protein that self-assemble into uniform 25 nm particles. The study presents them as the vaccine antigen produced by the optimized BEVS platform.
Source:
FPV vaccine antigen design
Source:
safe and immunogenic vaccine development
Problem solved
They offer a safe and immunogenic vaccine format for FPV while avoiding use of infectious virus.; providing a noninfectious immunogenic FPV vaccine format
Source:
They offer a safe and immunogenic vaccine format for FPV while avoiding use of infectious virus.
Source:
providing a noninfectious immunogenic FPV vaccine format
Problem links
providing a noninfectious immunogenic FPV vaccine format
LiteratureThey offer a safe and immunogenic vaccine format for FPV while avoiding use of infectious virus.
Source:
They offer a safe and immunogenic vaccine format for FPV while avoiding use of infectious virus.
Published Workflows
Objective: Engineer a baculovirus donor-plasmid system that increases FPV VP2 production sufficiently to generate immunogenic VLPs and evaluate their protective efficacy.
Why it works: The workflow is presented as effective because donor-plasmid optimization increases VP2 production metrics, enabling purification of VP2 that self-assembles into VLPs, which are then tested for immunogenicity and protection in animals.
enhanced recombinant protein transcriptionself-assembly of VP2 into virus-like particlesdonor plasmid optimization in BEVSqPCR quantificationSDS-PAGE/Western blottingtransmission electron microscopyfunctional assaysserological analysisneutralizing antibody detectionpost-challenge clinical monitoring
Stages
- 1.BEVS donor-plasmid optimization(library_design)
This stage exists to address the low-yield constraint of recombinant protein production in insect cell expression systems.
Selection: incorporation of hr1-p6.9-p10 transcriptional enhancer and Ac-ie-01 anti-apoptotic gene to enhance recombinant protein production
- 2.production and characterization of VP2 VLPs(functional_characterization)
This stage exists to confirm that increased production yields a structurally and functionally relevant VLP product.
Selection: quantification of VP2 expression, viral titers, hemagglutination activity, and VLP morphology
- 3.animal immunogenicity and protection testing(confirmatory_validation)
This stage exists to confirm that the produced VLPs are not only well expressed and assembled but also immunogenic and protective in relevant animals.
Selection: serological responses, neutralizing antibodies, and post-challenge clinical outcomes in mice and cats
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The abstract supports that production depends on recombinant VP2 expression, purification, and characterization by TEM and functional assays, followed by immunogenicity testing in mice and cats.; requires recombinant VP2 protein production and purification
The abstract does not show that VLPs alone solve the upstream expression-yield bottleneck without the optimized BEVS platform.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Purified VP2 protein self-assembled into uniform 25 nm virus-like particles.
particle diameter 25 nm
Immunization with the FPV VLP product elicited earlier responses than commercial vaccines.
Vaccinated cats maintained normal body temperature, stable leukocyte counts, and minimal viral shedding after FPV challenge.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug fpv-vp2-virus-like-particles
The purified protein self-assembled into uniform 25 nm virus-like particles (VLPs).
Source:
assembly propertysupports
Purified VP2 protein self-assembled into uniform 25 nm virus-like particles.
Source:
immunogenicity comparisonsupports
Immunization with the FPV VLP product elicited earlier responses than commercial vaccines.
Source:
protective efficacysupports
Vaccinated cats maintained normal body temperature, stable leukocyte counts, and minimal viral shedding after FPV challenge.
Source:
Comparisons
Source-stated alternatives
The abstract explicitly compares immunization timing against commercial vaccines.
Source:
The abstract explicitly compares immunization timing against commercial vaccines.
Source-backed strengths
self-assembles into uniform particles; highly immunogenic; associated with rapid-onset protection
Source:
self-assembles into uniform particles
Source:
highly immunogenic
Source:
associated with rapid-onset protection
Ranked Citations
- 1.